Skip to main content
    R

    Repligen Corporation (RGEN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $162.78
    -5.01 (-2.99%)

    Market Cap: $10.73B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Repligen Corporation (RGEN) Earnings: Report Dates and Results

    Updated Oct 27, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Repligen (RGEN) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Repligen reported EPS of $0.53, above the $0.46 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    83%(33/40)
    Avg Surprise
    +19.08%
    Streak
    5 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.53
    Range$0.49 - $0.57
    19 analysts
    Revenue Consensus
    $244.68M
    Range$215.01M - $257.99M
    20 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.60
    Range$0.53 - $0.67
    10 analysts
    EPS Revisions
    4
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$0.59+0.9%
    60d ago$0.59+0.9%
    30d ago$0.59+1.5%
    7d ago$0.59+0.9%
    Current$0.60
    Revenue Consensus
    $250.28M
    Range$245.60M - $252.70M
    10 analysts

    Next Report

    RGEN has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.2% above the $0.49 reported for the quarter ended Dec 31, 2025.

    RGEN Earnings Call

    The latest RGEN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, RGEN beat 33, missed 4 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $209.31M, up 10.9% from $188.81M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.53$0.46$0.41 - $0.50+15.22%Beat+15.2%171 up, 2 downOct 27, 2026$209.31M
    Jun 30, 2026$0.54$0.45$0.41 - $0.47+20.00%Beat+45.9%170 up, 1 downJul 28, 2026$204.13M
    Mar 31, 2026$0.48$0.39$0.37 - $0.41+23.08%Beat+23.1%171 up, 3 downMay 5, 2026$194.25M
    Dec 31, 2025$0.49$0.44$0.42 - $0.50+11.52%Beat+11.4%181 up, 1 downFeb 24, 2026$197.91M
    Sep 30, 2025$0.46$0.41$0.39 - $0.45+12.20%BeatN/A182 up, 2 downOct 28, 2025$188.81M
    Jun 30, 2025$0.37$0.39$0.35 - $0.44-5.13%Miss+12.1%181 up, 2 downJul 29, 2025$182.37M
    Mar 31, 2025$0.39$0.35$0.31 - $0.38+11.43%Beat+39.3%173 up, 1 downApr 29, 2025$169.17M
    Dec 31, 2024$0.44$0.42$0.35 - $0.46+4.99%Beat+33.3%150 up, 0 downFeb 20, 2025$167.55M
    Sep 30, 2024-$0.01$0.33$0.28 - $0.39-103.55%Miss-105.1%141 up, 0 downNov 12, 2024$154.87M
    Jun 30, 2024$0.33$0.33$0.26 - $0.360.00%In line-37.7%130 up, 0 downJul 30, 2024$158.84M
    Mar 31, 2024$0.28$0.30$0.27 - $0.34-6.67%Miss-56.3%121 up, 0 downMay 1, 2024$153.18M
    Dec 31, 2023$0.33$0.33$0.30 - $0.350.00%In line-51.5%110 up, 0 downFeb 21, 2024$166.62M
    Sep 30, 2023$0.23$0.16$0.09 - $0.30+43.75%Beat-70.1%131 up, 2 downOct 31, 2023$141.19M
    Jun 30, 2023$0.53$0.48$0.40 - $0.54+10.42%Beat-41.8%130 up, 1 downAug 2, 2023$159.17M
    Mar 31, 2023$0.64$0.59$0.55 - $0.63+8.47%Beat-30.4%121 up, 0 downMay 2, 2023$165.38M
    Dec 31, 2022$0.68$0.58$0.54 - $0.62+17.24%Beat-16.0%110 up, 0 downFeb 22, 2023$186.76M
    Sep 30, 2022$0.77$0.68$0.62 - $0.77+13.24%Beat-1.3%90 up, 1 downNov 1, 2022$200.74M
    Jun 30, 2022$0.91$0.71$0.66 - $0.75+28.17%Beat+15.2%80 up, 1 downAug 2, 2022$207.63M
    Mar 31, 2022$0.92$0.72$0.66 - $0.76+27.78%Beat+35.3%80 up, 0 downApr 27, 2022$206.40M
    Dec 31, 2021$0.81$0.65$0.64 - $0.66+24.62%Beat+55.8%80 up, 0 downFeb 17, 2022$186.52M
    Sep 30, 2021$0.78$0.64$0.62 - $0.66+21.88%Beat+95.0%80 up, 0 downOct 28, 2021$178.22M
    Jun 30, 2021$0.79$0.52$0.48 - $0.56+51.92%Beat+88.1%8N/AJul 27, 2021$162.96M
    Mar 31, 2021$0.68$0.42$0.40 - $0.47+61.90%Beat+112.5%8N/AMay 4, 2021$142.84M
    Dec 31, 2020$0.52$0.31$0.29 - $0.32+67.74%Beat+160.0%8N/AFeb 24, 2021$108.65M
    Sep 30, 2020$0.40$0.28$0.26 - $0.31+42.86%Beat+53.8%7N/ANov 5, 2020$94.06M
    Jun 30, 2020$0.42$0.28$0.24 - $0.31+50.00%Beat+35.5%7N/AJul 30, 2020$87.46M
    Mar 31, 2020$0.32$0.21$0.13 - $0.23+52.38%Beat+14.3%9N/AMay 6, 2020$76.09M
    Dec 31, 2019$0.20$0.18$0.17 - $0.20+11.11%Beat-4.8%9N/AFeb 20, 2020$69.47M
    Sep 30, 2019$0.26$0.19$0.18 - $0.22+36.84%Beat+30.0%8N/AOct 31, 2019$69.44M
    Jun 30, 2019$0.31$0.30$0.19 - $0.30+3.33%Beat+93.8%5N/AAug 1, 2019$70.69M
    Mar 31, 2019$0.28$0.22$0.18 - $0.26+27.27%Beat+64.7%7N/AMay 9, 2019$60.63M
    Dec 31, 2018$0.21$0.21$0.19 - $0.220.00%In line+5.0%8N/AFeb 21, 2019$7.14M
    Sep 30, 2018$0.20$0.18$0.16 - $0.19+11.11%Beat+33.3%9N/ANov 1, 2018$49.53M
    Jun 30, 2018$0.16$0.18$0.16 - $0.20-11.11%Miss-20.0%9N/AAug 2, 2018$47.73M
    Mar 31, 2018$0.17$0.15$0.13 - $0.18+13.33%Beat+13.3%9N/AMay 8, 2018$89.63M
    Dec 31, 2017$0.20$0.12$0.11 - $0.14+66.67%Beat+150.0%9N/AFeb 22, 2018$41.61M
    Sep 30, 2017$0.15$0.11$0.09 - $0.15+36.36%Beat+87.5%6N/ANov 9, 2017$36.58M
    Jun 30, 2017$0.20$0.15$0.14 - $0.16+33.33%Beat+25.0%6N/AAug 3, 2017$32.45M
    Mar 31, 2017$0.15$0.13N/A+15.38%Beat+25.0%N/AN/AMay 4, 2017$30.59M
    Dec 31, 2016$0.08$0.07N/A+14.29%Beat+700.0%N/AN/AFeb 22, 2017$130.04M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.71, up 64.7% from the year before. It was $0.44 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.71+64.7%
    Dec 31, 2024$1.04-40.0%
    Dec 31, 2023$1.73-47.3%
    Dec 31, 2022$3.28+7.2%
    Dec 31, 2021$3.06+84.3%
    Dec 31, 2020$1.66+58.1%
    Dec 31, 2019$1.05+41.9%
    Dec 31, 2018$0.74N/A
    Dec 31, 2017$0.70+59.1%
    Dec 31, 2016$0.44N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,800 words across 16 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,82416
    2026Q2Jun 30, 20268,79716
    2026Q1Mar 31, 20268,65516
    2025Q4Dec 31, 20257,97815
    2025Q3Sep 30, 20257,64717
    2025Q2Jun 30, 20253,4264
    2025Q1Mar 31, 20259,42713
    2024Q4Dec 31, 20247,84315

    2026Q3 Earnings Call

    Opening remarks

    Jacob K. Johnson Vice President of Investor Relations Thank you, operator, and good morning, everyone. Welcome to Repligen's 2026 third quarter earnings call. Joining me today are President and Chief Executive Officer Olivier Loeillot, and Chief Financial Officer Jason Garland. Earlier this morning, we issued our earnings release and supplemental presentation, which are available on the Investor Relations section of our website. Before we begin, please note that today's discussion will include forward-looking statements and certain non-GAAP financial measures. Actual results may differ materially from those expressed or implied by these statements due to risks and uncertainties described in today's earnings release and our SEC filings. Reconciliations of non-GAAP to GAAP measures are included in today's earnings release and supplemental materials. These adjusted financial measures should not be viewed as an alternative to GAAP measures, but are intended to best reflect the performance of our ongoing operations. With that, I will turn the call over to Olivier Loeillot.

    Olivier Loeillot President and Chief Executive Officer Thank you, Jacob. Good morning, everyone, and welcome to our 2026 third quarter call. We had a record quarter with $209 million of revenue. This is a significant milestone as we surpassed our prior peak in the second quarter of 2022. We believe this is another proof point that the industry is poised for its next phase of growth. It also highlights the benefits of our diversified portfolio, and this was driven in part by proteins and chromatography. In addition, we were delighted to close the acquisition of BioLife earlier this month. This combination further expands our capabilities in the rapidly growing cell therapy end market and strengthens our long-term growth platform. We will discuss our initial observations and integration efforts in a moment. But first, we delivered $209 million of revenue in the third quarter, which represented 12.5% organic growth while expanding adjusted operating margins by 170 basis points compared to the prior year. This was an excellent result as we were lapping a very strong quarter in the prior year. Our ability to outpace market growth very significantly this quarter is a testament to our team's strong execution in a market that is still recovering. Following these strong results, incorporating the BioLife acquisition, we are increasing our full-year 2026 guidance. Jason will provide more details. Our updated 2026 guidance includes an expected $24 million revenue contribution from BioLife for the period following its close in our fourth quarter. This assumes BioLife's annual 2026 revenue on a pro forma basis will be approximately $114 million, above the midpoint of BioLife's most recent guidance. The business is performing well, and we are very confident about delivering our deal model for 2027 and beyond.

    Frequently Asked Questions About RGEN

    When is Repligen's next earnings date?

    Repligen's next earnings report is expected for Feb 22, 2027.

    Did RGEN beat earnings estimates last quarter?

    Yes. Repligen reported EPS of $0.53 for the quarter ended Sep 30, 2026, above the $0.46 estimate, a 15.22% surprise.

    What EPS do analysts expect from RGEN next quarter?

    The consensus EPS estimate for Repligen for the quarter ending Dec 31, 2026 is $0.53 from 19 analysts, with estimates from $0.49 to $0.57.

    How often does RGEN beat earnings estimates?

    Repligen beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +11.66%.